Company: STAA
Filing Date: 2025-02-21
Form Type: 10-K
Source: 0000950170-25-024813
Chunk: 153

Company: STAAR SURGICAL CO
Filing Date: 2025-02-21
Form: 10-K
Item: Item 7
Chunk 153
---

    $
    18,525

    $
    21,319

*	Refer to the Notes to the Consolidated Financial Statements in this Annual Report on Form 10-K.

Overview of changes in cash and cash equivalents and other working capital accounts

The following table presents a summary of cash flows for the fiscal years presented (dollars in thousands):

    2024

    2023

    2022

    Cash flows from:

    Operating activities
     
    $
    15,725

    $
    14,594

    $
    35,715

    Investing activities

    (59,217
    )

    74,347

    (156,376
    )

    Financing activities

    5,724

    7,415

    8,297

    Effect of exchange rate changes

    (1,111
    )

    202

    (862
    )

    Net change in cash and cash equivalents

    (38,879
    )

    96,558

    (113,226
    )

    Cash and cash equivalents, at beginning of year

    183,038

    86,480

    199,706

    Cash and cash equivalents, at end of year
     
    $
    144,159

    $
    183,038

    $
    86,480

For 2024, cash provided by operating activities consisted of $41.3 million in non-cash items primarily related to stock-based compensation expenses, partially offset by a $20.2 million net loss and $5.4 million in working-capital changes primarily related to the capitalization of cloud-based software and changes in inventories, partially offset by changes in accounts receivable.  For 2023, cash provided by operating activities consisted of $34.1 million in non-cash items primarily related to stock-based compensation expenses and $21.3 million in net income, offset by $40.8 million in working-capital changes primarily related to changes in accounts receivable and inventories, partially offset by changes in other current liabilities.  For 2022, cash provided by operating activities consisted of $39.7 million in net income and $24.9 million in non-cash items primarily related to stock-based compensation expenses, offset by $28.9 million in working-capital changes primarily related to changes in accounts receivable. 

Since 2022 we decided to invest our cash